Benaroya Research Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Benaroya Research Institute sits in the top decile of US sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count).

28 total trials 4 currently recruiting 23 completed early-phase tilt top decile by trial count

Benaroya Research Institute: 28 sponsored US clinical trials, 4 recruiting.

Benaroya Research Institute sponsors 28 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 23 completed. 4 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pain, with 2 trials.

Top-decile sponsor footprint

Benaroya Research Institute ranks in the top decile of sponsors by registered trial count (#568 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 79/100

23 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

28 total, page 1 of 1

RECRUITING

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929

RECRUITING Phase 3

A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population

NCT06585540

RECRUITING NA

Antibiotic Usage Prior to OnabotulinumtoxinA Injection

NCT04754737

RECRUITING Phase 4

Optimizing Pain Control in Transurethral Resection of the Prostate

NCT04102566

COMPLETED NA

Do Patient Educational Videos Improve Pain and Recovery After Laparoscopic Hysterectomy?

NCT06265376

COMPLETED Early Phase 1

Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

NCT05281614

COMPLETED Early Phase 1

Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D

NCT05847413

COMPLETED Phase 3

Opioid-free Anesthesia for Open Cardiac Surgery: A Prospective Randomized Controlled Trial

NCT04197570

COMPLETED NA

Temporal Variation in Exhaled Volatile Organic Compounds in Esophageal Cancer Patients

NCT06453993

COMPLETED

Defining Normal Postoperative Magnetic Resonance Imaging After Total Knee Arthroplasty

NCT04821245

COMPLETED

Influence of Nutrition and Sarcopenia on Esophageal Cancer Outcomes

NCT06314516

COMPLETED NA

Impact of Catheter Size on Peri-Operative Pain After Robotic Assisted Laparoscopic Prostatectomy

NCT04098809

COMPLETED NA

Transversus Abdominus Plane Catheters for Open Inguinal Hernia Repair

NCT02741492

COMPLETED NA

Proximal Versus Distal Adductor Canal Blocks for Total Knee Arthroplasty

NCT02701114

COMPLETED NA

Evaluation of Supraclavicular, Suprascapular, and Interscalene Nerve Blocks for Outpatient Shoulder Surgery

NCT02287142

COMPLETED NA

Comparison of Pulmonary Function and Efficacy of Different Nerve Block Catheters for Shoulder Surgery

NCT02117778

COMPLETED Phase 2

Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults

NCT01650870

COMPLETED NA

Intraoperative Radiation Therapy in Early Stage Breast Cancer

NCT02266602

COMPLETED Phase 1

Study on the Safety of Abatacept in Relapsing Polychondritis

NCT01272856

COMPLETED Phase 1

Kristalose as Bowel Evacuant Prior to Colonoscopy

NCT01256541

COMPLETED NA

Neuraxial Ultrasound for Thoracic Epidural Placement

NCT02785055

COMPLETED NA

Effects of Perioperative B&O Suppositories on Post-op Pain and Morphine Use After Laparoscopic Prostatectomy

NCT00863928

COMPLETED Phase 2

Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

NCT00761241

TERMINATED Phase 2

Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

NCT00577356

COMPLETED Phase 4

Preventing Propofol-associated Injection Pain

NCT00864682

COMPLETED Phase 2

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

NCT00343044

COMPLETED Phase 2

Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

NCT00349557

COMPLETED Phase 2

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

NCT00242918

What is open in the Benaroya Research Institute pipeline

4 recruiting of 28 indexed (14% open); 23 completed (82%).

Phase mix: 4 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Pain (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Benaroya Research Institute: open-pipeline peers nationwide

Peers matched on 28 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Benaroya Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%5%10%15%20%25% Total trials Recruiting share Benaroya Research InstituteAxsome TherapeuticsCAMC Health SystemCTI BioPharmaHarvard Pilgrim Health CareAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Benaroya Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Benaroya Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 28 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Benaroya Research Institute page

28 registered trials is a research-attention snapshot, not an endorsement of Benaroya Research Institute or any single study.

  • 4 of Benaroya Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pain is the condition Benaroya Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Benaroya Research Institute pipeline card: 28 registered trials from official public datasets.Report a data error.